Background: Suboptimal immunosuppression after kidney transplantation con-
| INTRODUC TI ON
Tacrolimus has a narrow therapeutic window with high inter-patient pharmacokinetic variability, requiring close monitoring of blood trough concentrations (initial goal 8-12 ng/mL) and frequent early dose adjustments to reduce the risk of poor outcomes.
Concentrations above the therapeutic range are associated with adverse effects such as nephrotoxicity, while sub-therapeutic concentrations may increase the risk of acute rejection (AR) and graft failure (GF). 1 Many factors have been identified contributing to TAC inter-patient pharmacokinetic variability such as drug-drug interactions, drug-food interactions, changes in hepatic metabolism, and nonadherence. 2 Genetic factors are also well-known to account for TAC pharmacokinetics differences between patients and several single-nucleotide polymorphisms (SNPs) have been associated with TAC troughs, including CYP3A5*3, CYP3A5*6, CYP3A5*7, CYP3A4*22, and possibly POR*28.
3-6 CYP3A5*3, *6, and *7 variants are lossof-function alleles and significantly reduce the metabolic clearance of TAC. 3 The CYP3A5*3 allele occurs more frequently in European Americans (EA; ~95%) than in African Americans (AA; ~31%), while the *6 and *7 alleles are common in AA (5%-12%), but absent in most EA.
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Studies on the impact of TAC trough intra-patient variability (mostly obtained in the first year post-transplant) have not been consistent, but generally point toward worse outcomes at higher levels of variability. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Older studies showed that intra-patient variability in cyclosporine exposure and trough concentration was associated with poorer outcomes. [21] [22] [23] [24] [25] [26] [27] [28] Borra et al 10 in 2010 were the first to describe an association between high intra-patient variability in TAC clearance in months 6-12 and a composite endpoint of graft failure.
Rodrigo et al 11 reported that individuals with TAC trough CV >30% at 4-12 months post-transplant were at greater risk of death-censored graft loss and development of de novo donor-specific antibodies. Vanhove et al 19 showed that TAC trough CV >22% between 6-12 months post-transplant was associated with more moderate to severe fibrosis and tubular atrophy on biopsy by 2 years. Similar studies showed association between high intra-patient TAC trough variability and acute rejection, decline in glomerular filtration rate, graft loss, or composites thereof. 12, 17, 18 A study by Taber et al 20 of
TAC troughs beginning at 1 month post-transplant showed that high trough variability was associated with a higher risk of acute rejection and graft loss. To our knowledge, no study has previously investigated the impact of intra-patient variability in TAC dose on kidney transplant outcomes.
Early acute rejection occurs in less than 10% of kidney transplant recipients by 6 months and in less than 15% by 2 years, 29 but
is an important risk factor for graft loss. [30] [31] [32] To effectively test the impact of intra-patient variability of TAC dose or trough on rejection, a sufficiently large population is required. We aimed to identify whether early intra-patient TAC variability in troughs and doses is associated with acute rejection and graft failure in kidney transplant recipients enrolled in the Deterioration of Kidney Allograft Function (DeKAF) Genomics study. We also sought to evaluate if CYP3A5 loss-of-function alleles contribute to intra-patient TAC variability. Understanding how much intra-patient variability is tolerable may provide opportunities to improve short-and long-term outcomes.
| ME THODS

| Study population
Subjects were kidney allograft recipients, receiving TAC maintenance in the DeKAF Genomics study, which is a prospective, observational study that enrolled kidney and simultaneous pan- 
| Genotyping
| Statistical analysis
The coefficient of variation (CV) was used as the measure for intrapatient TAC dose and trough variability. The CV was defined as the ratio of standard deviation (SD) to the mean in percent and was 
| RE SULTS
| Tacrolimus trough concentration and dose variability
We studied 246 AA and 1226 EA transplant recipients. Demographics and clinical factors are shown in 
| Acute rejection
Ninety-seven acute rejections (6.6%) in 1472 recipients occurred in the first 6 months. In AA, rejecters had a median TAC trough concentration of 5.71 ng/mL compared to 6.82 ng/mL in non-rejecters. In EA, rejecters had a median TAC trough concentration of 9.07 ng/mL compared to 8.92 in non-rejecters. Variability of TAC dose was higher in those who experienced acute rejection ( Figure 1 and Table S1 ). In multivariate Cox regression analysis, the highest quartiles of CV of TAC dose (CV > 19% for AA; CV > 24% for EA) was a significant risk factor for acute rejection compared to the lower three quartiles in AA (HR: 33.53, P = 0.0001) and EA (HR:
1.81, P = 0.012; Table 3 ). After controlling for variability in TAC dose, each loss-of-function allele was associated with 84% lower hazard of acute rejection relative to those with no loss-of-function alleles in AA (HR: 0.16, P = 0.0015) while in EAs, the number of loss-of-function alleles was not associated with a change in the hazard of acute rejection (HR: 1.51, P = 0.26; Figure 2 and Table 3 ).
Variability in TAC troughs did not significantly influence the risk of acute rejection in either of our AA or EA cohorts (all P > 0.15, data not shown).
| Graft failure
There were 54 (21.8%) graft failures in the AA recipients and 141 (12.8%) in the EA recipients. AAs with graft failure had a median TAC trough concentration of 6.3 ng/mL in the first 6 months compared to 6.6 ng/mL in those without failure. European Americans with graft failure had a median TAC trough concentration of 8.2 ng/ mL compared to 8.3 ng/mL in those without failure. In multivariate Cox regression analysis, the highest quartiles of CV of TAC dose (CV > 31% for AA; CV > 38% for EA) were significant risk factors for graft failure compared to the lower three quartiles in AA (HR: 2.06, P = 0.022) but not in EA recipients (HR: 1.39, P = 0.097) (Table 4A) .
Variability in the highest quartiles of TAC troughs (CV > 49% for AA;
CV > 38% for EA) significantly increased the risk of graft failure in both the AA cohort (HR: 2.95, P = 0.0002) and the EA cohort (HR:
1.53, P = 0.024). The number of CYP3A5 loss-of-function alleles did not reach retention thresholds of P < 0.10 in our final graft failure models.
| Tacrolimus variability and CYP3A5 loss-offunction alleles
One or two loss-of-function CYP3A5 alleles were carried by 99.5% of EA recipients, whereas 78% of AA carried one or two loss-of-function allele (Table 1) . Highest variability in TAC troughs was observed in recipients with no loss-of-function alleles while higher variability in TAC dose was found in recipients with two loss-of-function alleles (Tables S1 and S2 ). In EA recipients, the number of CYP3A5 loss-of-function alleles was significantly associated with TAC trough variability and dose variability ( Table 2 ).
The reduction in % absolute change of CV of trough with more loss-of-function alleles is due to additional CYP3A5 loss-of-function alleles decreasing the SD of TAC troughs more than trough means therefore CVs of troughs decreasing overall. Conversely, additional CYP3A5 loss-of-function alleles decreased dose means more than the SD of doses, resulting in an overall increase in % absolute change of CV of dose. In AA recipients, the trends were similar but neither trough or dose variability was significantly associated with CYP3A5 loss-of-function alleles.
| D ISCUSS I ON
This study investigated the influence of early intra-patient TAC pharmacokinetic variability in trough and dose on acute rejection and all-cause graft failure in a large cohort of kidney transplant recipients. We also characterized the influence of common CYP3A5 loss-of-function variants on variability and acute rejection. Previously, we identified high variability between patients in TAC trough and dose in EA and AA subjects and showed in a genome-wide association study that CYP3A5*3, *6, and *7 lossof-function alleles and clinical factors accounted for 53.9% of the observed variability in troughs among AA recipients 3 and ~40% of variability among EA recipients. 36 Other small studies have associated CYP3A5 genotype with TAC pharmacokinetic variability, although with mixed results. [37] [38] [39] In this study, we sought to understand if TAC trough and dose variability were important clinical factors that should be considered in developing tools to improve post-transplant care.
Several papers have been published studying TAC variability.
These studies generally had smaller sample sizes (n < 400), focused on later TAC measurements (6-12 months post-transplant), did not evaluate variability in TAC dose, and, with the exception of a study by Ro et al, did not assess genetic variables. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Previous studies have mostly excluded early TAC measurements because it is presumed that therapeutic drug monitoring is aggressive during this period and that close contact is maintained with the provider, resulting in more stable immunosuppression. In comparison, our study evaluated a larger cohort and focused on early TAC troughs and doses. A more recent study by Taber et al 20 also included earlier intra-patient TAC trough variability starting at one month prost-transplant in a larger cohort and showed that trough variability was higher in AA (CV 39.9%) compared to non-AA recipients (CV 34.8%), which is consistent with our findings.
Our first aim was to investigate the influence of TAC trough variability on post-transplant outcomes. In our study, we did not find an association between intra-patient TAC trough variability and acute rejection in either cohort, possibly due to our focus on early TAC troughs within the first 6 months post-transplant when induction therapy immunosuppressive effects persist. This is consistent with the findings by Taber et al that TAC trough variability is not a risk factor for rejection in EA. Their group, however, did find that TAC trough variability was a risk factor for rejection in AA, possibly due to their larger number of AA recipients, where we may have had too few to detect the effect. Our results should not be considered contradictory, but rather complimentary to previous findings, as studies have been widely inconsistent regarding the association between TAC trough variability and AR Pollock, Hsiau, Ro, Prytula, and Taber (AA cohort) showed association between TAC trough variability and acute rejection, 13-16 while Schmid, Rodrigo, and Taber (EA cohort) did not. 8, 11, 20 We did, however, find a strong association between early TAC trough variability and all-cause graft failure, which is consistent with previous studies. [10] [11] [12] [13] We found that EA recipients with TAC trough variability >38% and AA recipients with trough variability >49%
were at increased risk (Table 4B) . Poor immune control in the early 
TA B L E 1 Recipient demographics and clinical characteristics
TA B L E 1 (Continued)
post-transplant period may contribute to worse long-term outcomes.
Early immune dysfunction and acute rejection events may mediate immunologic damage, resulting in a slow decline in organ function and graft failure. Additionally, patients who potentially experience high early variability due to poor adherence may remain poorly adherent beyond 6 months after transplant, causing suboptimal long-term immunosuppression.
Our second aim was to investigate the effects of TAC dose intra-patient variability. We found that high TAC dose variability in the early post-transplant period is associated with a greater risk of acute rejection (Table 3 , Figure 1 ). European American recipients with dose variability >24% and AA recipients with dose variability >19% were at increased risk. The wide confidence interval in the AA analysis is likely due to the small number of only 14 rejection events in this group by 6 months post-transplant and should be interpreted with caution. Additionally, we found that high TAC dose variability (CV > 31%) was a significant risk factor for graft failure in the AA population (Table 4A) . Coefficient of variations were overall larger in the GF analyses compared to the AR analyses; however, this stems from the difference in calculation methods rather than from a biological cause. 
TA B L E 2 Change in tacrolimus trough
and dose variability per additional CYP3A5 loss-of-function allele (*3, *6 or *7) a but could trigger dose changes which lead to dose over-adjustments and periods of even greater sub-or supra-therapeutic troughs that occur in the days or weeks before the next trough measurement.
Nonadherence has been described as a major risk of poor kidney transplant outcomes and is often proposed as a cause of high variability in TAC trough concentrations and dose adjustments. alleles, TAC metabolism is significantly higher. This leads to the observation of very low TAC troughs despite high TAC doses. Clinicians may be less familiar with the dose-response patterns in these patients, may not "believe" low troughs, and may be less inclined to increase the dose appropriately. It is reasonable to conclude that dose adjustments in moderation are needed to achieve optimal immunosuppression, while excessive changes are either reflective of posttransplant complications or of over-adjustments causing prolonged intervals outside the therapeutic range.
In our AA cohort, each CYP3A5 loss-of-function allele was significantly associated with a reduction in the risk of acute rejection (Table 3) . Approximately 25% carried no loss-of-function alleles, Our study has several additional limitations. This analysis is based on data from an observational study in which trough measurements and doses were not overseen by study staff. The number and timing of measured TAC trough concentrations and corresponding doses were not standardized to a specific day among recipients, which could have artificially lowered CVs for patients with fewer measurements. However, calculating CV values from each set of five consecutive measurements and accounting for correlation among observations from the same patient in our models allows us to minimize this potential for bias in the AR analyses. Additionally, the relatively small size of our AA cohort and the low frequency of acute rejection events in this group may have influenced some of our results, specifically inflating the hazard ratio of high variability in TAC dose on acute rejection risk and limiting the statistical significance of the association trends between CVs and CYP3A5 loss-of-function alleles. Drug-food interactions, diarrhea, and nonadherence have been reported to contribute to intra-patient variability in TAC trough concentrations. 2 These factors were not included in our models and may have affected variability. Drug-drug interactions are also known to affect variability and we controlled for steroid use. However, the goal of this study was not to identify all the factors related to variability but to study if variability in trough concentration and dose adversely affects transplant outcomes. Lastly, our study did not consider rarer genetic variants, such as CYP3A4*22 or POR*28, which have been shown to influence TAC metabolism to a lesser extent.
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| CON CLUS ION
This is a large study assessing the influence of early intra-patient TAC pharmacokinetic and dose variability on acute rejection and allcause graft failure in a cohort of kidney transplant recipients. We showed that intra-patient trough variability is higher in AAs compared to EAs. High CV of dose >24% and >19% is associated with greater hazard of early acute rejections in EA and AA, respectively.
CV of TAC trough >49% and >38% is associated with greater hazard of graft failure in AA and EAs recipients, respectively. In AA, 
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